NSCLC HARBORING EGFR MUTATIONS

Clinical trials for NSCLC HARBORING EGFR MUTATIONS explained in plain language.

Never miss a new study

Get alerted when new NSCLC HARBORING EGFR MUTATIONS trials appear

Sign up with your email to follow new studies for NSCLC HARBORING EGFR MUTATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Double-Drug attack: new combo aims to tackle tough lung cancer

Disease control Not yet recruiting

This trial investigates whether combining two drugs—JS212 (given by IV) and JS111 (taken orally)—can safely and effectively shrink tumors in people with advanced non-small cell lung cancer that has a specific EGFR mutation. About 20 participants who have not had prior treatment f…

Matched conditions: NSCLC HARBORING EGFR MUTATIONS

Phase: NA • Sponsor: Huan Zhou • Aim: Disease control

Last updated Jul 22, 2026 00:00 UTC

NSCLC HARBORING EGFR MUTATIONS

Get alerted when new NSCLC HARBORING EGFR MUTATIONS trials appear

Double-Drug attack: new combo aims to tackle tough lung cancer